Drugs / O6-BG
O6-BG
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00612638 | Jan 2005 → Jan 2007 | gliosarcoma | Duke University | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | O6-BG | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00612638 ↗ |
| Known as | O6-benzylguanine | “O6-benzylguanine (O6-BG)” NCT00612638 ↗ |
| Known as | O6-Benzylguanine-O6-BG | “O6-Benzylguanine-O6-BG” NCT00612638 ↗ |
| Route | Intravenous | “O6-BG administered intravenously 120mg/m2, over 1hr” NCT00612638 ↗ |